The latest data point for CVS's PEG Ratio, recorded in Q4'25, stands at -0.049, indicating a marginally negative valuation metric that suggests the stock may be undervalued relative to its earnings growth expectations. This value reflects a slight deterioration from the preceding Q3'25 figure of 0.012, within a timeframe spanning from Q1'23 to Q4'25. Over the analyzed period, the PEG Ratio exhibits high volatility, fluctuating between a low of -2.392 in Q3'24 and a high of 0.525 in Q3'23, with an overall trend shifting from predominantly negative values in early quarters to mixed but stabilizing signals in recent periods. Notable inflection points include a sharp recovery to positive territory in Q3'23 and Q2'24, followed by a plunge into deeper negatives in Q3'24, before rebounding toward near-neutral levels by Q4'25; Q1'25 lacks data, but the pattern underscores inconsistent growth perceptions for CVS. This area chart visualization highlights the metric's sensitivity to quarterly earnings and market dynamics, warranting caution for analysts evaluating long-term investment potential.